H100 CEO Eirik Grøttum purchased 407,163 shares of H100 through his associated company Kode Oslo for SEK 621,887, increasing insider holdings to over 5.3 million shares. This equity purchase is separate from H100's Bitcoin treasury, which remains at 3,506.4 BTC following a major Norwegian acquisition in August that added 2,455 BTC without cash payment. The acquisition involved issuing 790 million new shares, significantly diluting existing shareholders but increasing Bitcoin exposure. H100 is also considering future share buybacks under new Swedish rules, though no program has been announced yet. The CEO's purchase signals confidence in the company's strategy combining Bitcoin holdings with operational growth and capital market activities.
The H100 CEO's recent share purchase adds to insider holdings exceeding 5.3 million shares. For readers following major cryptocurrencies, here is Pluang's market snapshot as of Sep 17, 2026 17:02 WIB: out of 50 priced major cryptocurrencies, 43 rose and 6 fell. Notable movers include CAKE (PancakeSwap) with a 12.10% increase and a price of Rp42.674, COTI up 11.64% at Rp325, and BAL (Balancer) rising 11.14% with a price of Rp16.297.
BASF has agreed to sell its global mining solutions business to SNF, a specialty chemical company based in France, following a strategic review of BASF's Performance Chemicals division. The deal includes BASF's mining chemicals portfolio, production ...
TDG Gold Corp. has agreed to sell a 51% interest in its Aurora West property to Freeport-McMoRan for C$110 million in cash. Freeport also has an option to increase its ownership to 75% or 100% by funding an additional C$80 million in exploration and ...
Union Station Homeless Services is requesting community help to donate 627 frozen turkeys for its annual Dinner in the Park event, aiming to serve 6,000 Thanksgiving meals. The turkey drive will be held on November 16-17 in Pasadena, California. Dona...
Timeplast, a materials company with over 9,000 customers, has launched a Regulation A+ offering open to the public to license its patented water-soluble plastic technology. This plastic dissolves in water after a programmed period, reducing plastic w...
DelveInsight's 2026 report highlights more than 100 BCMA-targeted therapies in various clinical stages, focusing on multiple myeloma and other diseases. Leading pharma companies like Pfizer, Regeneron, and AstraZeneca are advancing treatments includi...
